Phase 3 prevention trial showed 81% reduced risk of symptomatic sars-cov-2 infections with subcutaneous administration of regen-cov™ (casirivimab with imdevimab)

Tarrytown, n.y., april 12, 2021 /prnewswire/ --  regen-cov rapidly protected household contacts from exposure to sars-cov-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks among individuals who developed symptomatic infections, regen-cov recipients cleared the virus faster and had much shorter symptom duration regeneron will share data with u.s. fda and request eua expansion to include covid prevention for appropriate populations, using a 1,200 mg subcutaneous dose regeneron pharmaceuticals, inc. (nasdaq: regn) today announced positive results from a phase 3 trial (2069a) assessing the ability of regen-cov™ (casirivimab with imdevimab) to reduce the risk and burden of covid-19 infection among household contacts of sars-cov-2 infected individuals.
REGN Ratings Summary
REGN Quant Ranking